Pure Global
NCT06388772

Study to Assess PK, Safety and Tolerability Early in Healthy Subjects

Phase I Clinical Study of Tolerability, Safety and Pharmacokinetics of QHRD106 Injection in Chinese Healthy Subjects With Single Doses
Changzhou Qianhong Bio-pharma Co., Ltd.·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Ischemic Stroke
Drug/Device/Intervention
QHRD106 Injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Changzhou Qianhong Bio-pharma Co., Ltd.
Location
Nanjing, China
Timeline & enrollment
Phase
Phase 1
Start date
Jul 05, 2021
End date
Jan 06, 2023
Enrollment
74 participants
Primary outcome

Safety as assessed by incidence, severity, and causality of adverse events,Plasma measurements of QHRD106

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of
 QHRD106 early in Chinese healthy subjects with single doses.

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedTransient cerebral ischaemic attack, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06388772
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06388772 through Pure Global AI's free database. This Phase 1 trial is sponsored by Changzhou Qianhong Bio-pharma Co., Ltd. and is currently Completed. The study focuses on Acute Ischemic Stroke. Target enrollment is 74 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.